Furthermore, in the randomized phase 3 BETH trial in early HER2 positive breast cancer patients the addition of bevacizumab to trastuzumab and chemotherapy had no effect on invasive disease free survival and OS at a median follow up of 38 months [50]. The gene discussed is ERBB2; the disease is breast carcinoma.